GlassScriptPhysician profile
Victoria D Case
NPI 1205824075
$4,552.13
in general payments reported to CMS, 2019-2025
33 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $881 · 2022: $1,345 · 2023: $1,280 · 2024: $572 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,326.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,614.19 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,348.08 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $148.69 | 2021-2023 | Nuplazid |
| Lilly USA, LLC | $135.56 | 2021-2025 | Emgality, Amyvid, Reyvow |
| Lundbeck LLC | $109.41 | 2021-2024 | Vyepti, Rexulti |
| Celgene Corporation | $104.55 | 2021-2024 | Zeposia |
| Novartis Pharmaceuticals Corporation | $102.54 | 2021-2023 | |
| Ucb, INC. | $101.08 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $92.52 | 2022-2024 | Rytary |
| Pfizer INC. | $75.97 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $73.44 | 2021-2022 | |
| Harmony Biosciences LLC | $58.13 | 2021-2022 | |
| Biogen, INC. | $46.72 | 2021-2022 | |
| Cala Health, INC. | $45.58 | 2025 | Cala Kiq |
| Neurocrine Biosciences, INC. | $44.35 | 2022-2025 | Ongentys, Ingrezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $42.90 | 2021 | |
| Impel Pharmaceuticals INC. | $40.42 | 2023 | Trudhesa |
| Genentech USA, INC. | $40.16 | 2021-2024 | Ocrevus, Enspryng |
| Kyowa Kirin, INC. | $34.08 | 2021-2023 | Nourianz |
| Janssen Pharmaceuticals, INC | $33.03 | 2022 | |
| Sk Life Science, INC. | $30.74 | 2021-2023 | |
| Eisai INC. | $30.41 | 2022 | |
| Ge Healthcare | $28.83 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.01 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.98 | 2021 | |
| Metacel Pharmaceuticals LLC | $19.32 | 2023 | Ozobax |
| Exact Sciences Corporation | $18.45 | 2025 | Cologuard Collection Kit |
| Mdd US Operations, LLC | $17.54 | 2023 | Gocovri |
| Genzyme Corporation | $17.27 | 2021 | |
| Emd Serono, INC. | $16.17 | 2021 | |
| Livanova USA, INC. | $13.53 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceuticals, INC. | $13.04 | 2021 | |
| Xeris Pharmaceuticals, INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.